PeerJ · 2026
Hs-CRP as a biomarker for atherosclerosis progression and cardiovascular risk: a systematic review.
СтатьяСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Al-Saedi Dalal A, Al-Otaibi Kholoud M, Alalhareth Ahmed, Aldurayhim Mohammed, Alomari Abdulmajeed, Aljadani Bushra, Siddiqui Jumana J, Alawaji Fadi, Almotiry Nourh T, Alloghbi Abdurahman
Аннотация
BACKGROUND: High-sensitivity C-reactive protein (hs-CRP) has emerged as a significant biomarker for assessing inflammatory activity in atherosclerosis, which may predict sudden death, especially in individuals with advanced atherosclerotic disease or those at high risk for acute events.
METHODS: This systematic review aimed to evaluate the significance of changes in hs-CRP levels over time in the population with atherosclerosis; the frequency of cardiovascular events, including mortality, stroke, and myocardial infarction; and changes in the progression of atherosclerosis. We conducted a comprehensive search of the PubMed, Scopus, Web of Science, and Embase databases up to January 2026 to identify observational and cohort studies evaluating high hs-CRP levels in patients with atherosclerosis, and to evaluate the quality of studies using the Newcastle-Ottawa Scale (NOS).
RESULTS: Our results included six studies involving baseline and follow-up hs-CRP values that showed a relationship between elevated baseline hs-CRP levels and an increased incidence of atherosclerotic progression that led to cardiovascular events. In addition, the variability in inflammation severity across different clinical events was displayed by the range of baseline hs-CRP measurements across different patient groups.
CONCLUSION: Universal screening for hs-CRP may improve assessment and thereby reduce the risk of cardiovascular events.
METHODS: This systematic review aimed to evaluate the significance of changes in hs-CRP levels over time in the population with atherosclerosis; the frequency of cardiovascular events, including mortality, stroke, and myocardial infarction; and changes in the progression of atherosclerosis. We conducted a comprehensive search of the PubMed, Scopus, Web of Science, and Embase databases up to January 2026 to identify observational and cohort studies evaluating high hs-CRP levels in patients with atherosclerosis, and to evaluate the quality of studies using the Newcastle-Ottawa Scale (NOS).
RESULTS: Our results included six studies involving baseline and follow-up hs-CRP values that showed a relationship between elevated baseline hs-CRP levels and an increased incidence of atherosclerotic progression that led to cardiovascular events. In addition, the variability in inflammation severity across different clinical events was displayed by the range of baseline hs-CRP measurements across different patient groups.
CONCLUSION: Universal screening for hs-CRP may improve assessment and thereby reduce the risk of cardiovascular events.